Authors: Prof. Dr. Jens Enno Wilkens, Prof. Dr. med. Horst Christian Vollmar
Publication: Federal Health Gazette (2022)
Type: Review article with scientific analysis of clinical observations
🔍What was observed?
This study analyzes the role of Hyperbaric Oxygen Therapy (HBOT) as an early therapeutic option for Long COVID—especially for symptoms such as:
persistent fatigue
cognitive disturbances ("brain fog")
headaches
shortness of breath or breathlessness
sleep disorders
🔬 The authors evaluate scientific literature, physiological foundations, and initial clinical reports.
➡️ Result: HBOT offers promising, side-effect-free potential, especially when used early in the post-COVID phase.
✨ Highlights & Emphases
"Especially in cases of fatigue, neurocognitive disorders, and circulation problems, HBOT appears to be a rational therapeutic option."
✅ HBOT affects cellular metabolism, microcirculation, and inflammatory responses
✅ Promising for Long-COVID patients without organic damage, but with functional deficits
✅ Therapy protocols often include: 30–40 sessions of 90 minutes each at 2 ATA pressure
✅ Well tolerated, even among younger patient groups
📌 Good to know
The work contains a well-founded overview of biological mechanisms of HBOT, such as:
Activation of genes for neovascularization
Stimulation of mitochondrial function
Reduction of chronic silent inflammations
Particularly exciting: HBOT acts at the cellular level, not just symptomatically
"Given the need for effective treatment options for Long COVID, HBOT should be integrated into future care concepts."
📈 Conclusion
The study clearly advocates for further research and application of HBOT in post-COVID care—especially where conventional medications are ineffective. It positions HBOT as a forward-thinking addition in rehabilitation medicine.
Study (PDF)
Study (PDF)
Legal Notice Terms and Conditions About Us
X4 Innovation GmbH © 2025 All Rights Reserved
